Patent · US Active

CRISPR effector system based diagnostics

US11174515B2 · kind B2 · utility

25Cited by
9References
60Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMar 15, 2018
Grant dateNov 16, 2021
Priority date
Expiry dateAug 13, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/80
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.